DB:USJ

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

USANA Health Sciences

Executive Summary

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. More Details


Snowflake Analysis

Flawless balance sheet with solid track record.


Similar Companies

Share Price & News

How has USANA Health Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: USJ is not significantly more volatile than the rest of German stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: USJ's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

1.6%

USJ

0.1%

DE Personal Products

1.4%

DE Market


1 Year Return

-5.3%

USJ

5.9%

DE Personal Products

0.9%

DE Market

Return vs Industry: USJ underperformed the German Personal Products industry which returned 1.8% over the past year.

Return vs Market: USJ underperformed the German Market which returned 0.6% over the past year.


Shareholder returns

USJIndustryMarket
7 Day1.6%0.1%1.4%
30 Day-11.3%2.7%8.7%
90 Day-4.6%6.8%2.3%
1 Year-5.3%-5.3%8.1%5.9%4.1%0.9%
3 Year4.9%4.9%36.9%27.7%3.9%-5.1%
5 Year-0.8%-0.8%69.8%51.4%24.8%7.1%

Long-Term Price Volatility Vs. Market

How volatile is USANA Health Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is USANA Health Sciences undervalued compared to its fair value and its price relative to the market?

47.0%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: USJ (€62.5) is trading below our estimate of fair value (€118.01)

Significantly Below Fair Value: USJ is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: USJ is good value based on its PE Ratio (13.9x) compared to the XE Personal Products industry average (20.8x).

PE vs Market: USJ is good value based on its PE Ratio (13.9x) compared to the German market (23.2x).


Price to Earnings Growth Ratio

PEG Ratio: USJ is poor value based on its PEG Ratio (12.2x)


Price to Book Ratio

PB vs Industry: USJ is overvalued based on its PB Ratio (4.1x) compared to the XE Personal Products industry average (2.4x).


Next Steps

Future Growth

How is USANA Health Sciences forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

1.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: USJ's forecast earnings growth (1.1% per year) is above the savings rate (0.2%).

Earnings vs Market: USJ's earnings (1.1% per year) are forecast to grow slower than the German market (27.3% per year).

High Growth Earnings: USJ's earnings are forecast to grow, but not significantly.

Revenue vs Market: USJ's revenue (3.1% per year) is forecast to grow slower than the German market (5.8% per year).

High Growth Revenue: USJ's revenue (3.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if USJ's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has USANA Health Sciences performed over the past 5 years?

3.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: USJ has high quality earnings.

Growing Profit Margin: USJ's current net profit margins (10.6%) are higher than last year (9.4%).


Past Earnings Growth Analysis

Earnings Trend: USJ's earnings have grown by 3.6% per year over the past 5 years.

Accelerating Growth: USJ's earnings growth over the past year (13.3%) exceeds its 5-year average (3.6% per year).

Earnings vs Industry: USJ earnings growth over the past year (13.3%) underperformed the Personal Products industry 16.3%.


Return on Equity

High ROE: USJ's Return on Equity (29.8%) is considered high.


Next Steps

Financial Health

How is USANA Health Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: USJ's short term assets ($386.0M) exceed its short term liabilities ($160.9M).

Long Term Liabilities: USJ's short term assets ($386.0M) exceed its long term liabilities ($27.6M).


Debt to Equity History and Analysis

Debt Level: USJ is debt free.

Reducing Debt: USJ had no debt 5 years ago.

Debt Coverage: USJ has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: USJ has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is USANA Health Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate USJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate USJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if USJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if USJ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of USJ's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

  • Explore strong dividend paying companies in the Household industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

4.0yrs

Average management tenure


CEO

Kevin Guest (57 yo)

4yrs

Tenure

US$4,157,827

Compensation

Mr. Kevin G. Guest serves as Chairman of the Board of USANA Health Sciences, Inc. since May 1, 2020. Mr. Guest has been the Chief Executive Officer of USANA Health Sciences, Inc. since November 23, 2016. M...


CEO Compensation Analysis

Compensation vs Market: Kevin's total compensation ($USD4.16M) is above average for companies of similar size in the German market ($USD1.56M).

Compensation vs Earnings: Kevin's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Kevin Guest
Chairman of the Board & CEO4yrsUS$4.16m0.019%
$ 250.2k
Jim Brown
President4yrsUS$2.09m0.049%
$ 649.5k
G. Hekking
Chief Financial Officer3.5yrsUS$1.47m0.0091%
$ 121.7k
Myron Wentz
Founder & Chairman Emeritus0.50yrno data40.34%
$ 540.0m
John Cuomo
Executive Director of Product Development & Technology7.92yrsno datano data
Patrique Richards
Executive Director of Investor Relations & Business Developmentno datano datano data
Ashley Collins
Vice President of Marketing & Public Relations3.92yrsno datano data
Ng Hean
Executive Vice President of South Asia3.83yrsno datano data
Sherman Ying
Executive Vice President of North Asia3.83yrsno datano data
Brian Dixon
Executive Director of Health & Science Education8.5yrsno datano data

4.0yrs

Average Tenure

54yo

Average Age

Experienced Management: USJ's management team is considered experienced (4 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Kevin Guest
Chairman of the Board & CEO4yrsUS$4.16m0.019%
$ 250.2k
Myron Wentz
Founder & Chairman Emeritus0.50yrno data40.34%
$ 540.0m
Gilbert Fuller
Lead Independent Directorno dataUS$228.20kno data
Peggie Pelosi
Independent Director1.92yrsUS$228.44k0.0052%
$ 69.5k
Robert Anciaux
Director24.33yrsUS$220.60k0.0020%
$ 27.0k
Timothy Wood
Independent Director1.08yrsUS$17.60k0.0020%
$ 27.0k
Christine Wood
Member of Scientific Advisory Councilno datano datano data
Monica Lewis
Member of Scientific Advisory Councilno datano datano data
Peter Rugg
Chairperson of Scientific Advisory Council16.83yrsno datano data
Bart Moore
Member of Scientific Advisory Councilno datano datano data
Heather Tick
Member of Scientific Advisory Councilno datano datano data
Frederic Winssinger
Independent Director4.5yrsUS$214.87k0.0064%
$ 86.1k

1.9yrs

Average Tenure

71yo

Average Age

Experienced Board: USJ's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: USJ insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

USANA Health Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: USANA Health Sciences, Inc.
  • Ticker: USJ
  • Exchange: DB
  • Founded: 1992
  • Industry: Personal Products
  • Sector: Household
  • Market Cap: US$1.594b
  • Listing Market Cap: US$1.339b
  • Shares outstanding: 21.04m
  • Website: https://www.usana.com

Number of Employees


Location

  • USANA Health Sciences, Inc.
  • 3838 West Parkway Boulevard
  • Salt Lake City
  • Utah
  • 84120
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
USNANYSE (New York Stock Exchange)YesCommon StockUSUSDNov 1994
USJDB (Deutsche Boerse AG)YesCommon StockDEEURNov 1994

Biography

USANA Health Sciences, Inc. develops, manufactures, and sells science-based nutritional and personal care products. The company offers USANA nutritional products that comprise essentials/CellSentials, such...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 20:04
End of Day Share Price2020/11/26 00:00
Earnings2020/09/26
Annual Earnings2019/12/28


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.